Clinical Trials

Nasopharyngeal Carcinoma

NCT06788002 2026-04-02

Light

26 enrolled

Phase 1/2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07247201 2026-03-30

AlloNK1

31 enrolled

Nasopharyngeal Carcinoma, Neoplasm, Residual

NCT07180173 2026-03-24

Upfront Neck Dissection Before Radiotherapy in Stage N3 Nasopharyngeal Carcinoma: A Retrospective Study

Completed

7 enrolled

Phase 1 Active not recruiting

Nasopharyngeal Carcinoma, Neoplasms

NCT02287311 2026-03-23

MABEL

38 enrolled 16 charts

Head & NeckLymphoid

Nasopharyngeal Carcinoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Smooth Muscle Tumor

NCT07320963 2026-03-20

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Phase 1/2 Not yet recruiting

52 enrolled

Nasopharyngeal Carcinoma

NCT05941741 2026-03-18

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

380 enrolled

Nasopharyngeal Carcinoma

NCT07362979 2026-03-17

Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

243 enrolled

Nasopharyngeal Carcinoma

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

266 enrolled

Nasopharyngeal Carcinoma

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

133 enrolled

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT07412314 2026-03-09

Proton Therapy for Recurrent Nasopharyngeal Carcinoma

Phase NA Recruiting

52 enrolled

Nasopharyngeal Carcinoma

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

593 enrolled

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07303283 2026-03-05

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

218 enrolled

Nasopharyngeal Carcinoma

NCT02597426 2026-03-04

Nasopharyngeal Carcinoma Post IMRT

Active not recruiting

108 enrolled

Nasopharyngeal Carcinoma

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Phase 1 Recruiting

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT07327216 2026-03-04

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

180 enrolled

Nasopharyngeal Carcinoma

NCT05389306 2026-03-03

NPC-LN

Phase NA Completed

348 enrolled

Nasopharyngeal Carcinoma, Disease

NCT06059261 2026-02-18

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

30 enrolled

Nasopharyngeal Carcinoma

NCT06636734 2026-02-11

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

28 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06592599 2026-02-10

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

24 enrolled

Nasopharyngeal Carcinoma

NCT02973386 2026-02-05

Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients

Phase 3 Completed

294 enrolled

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07388758 2026-02-05

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

37 enrolled

Phase 1 Active not recruiting

Nasopharyngeal Carcinoma

NCT02065362 2026-01-29

TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

14 enrolled

Nasopharyngeal Carcinoma, Camurati-Engelmann Syndrome

NCT07101744 2026-01-23

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

41 enrolled

Nasopharyngeal Carcinoma

NCT04509726 2026-01-20

EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma

Phase 1/2 Completed

9 enrolled

Nasopharyngeal Carcinoma

NCT05524168 2026-01-15

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

41 enrolled

Nasopharyngeal Carcinoma

NCT07340515 2026-01-14

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

300 enrolled

Nasopharyngeal Carcinoma

NCT03267498 2026-01-12

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

Phase 2 Completed

40 enrolled 14 charts

Nasopharyngeal Carcinoma

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

456 enrolled

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

346 enrolled

GastrointestinalHead & Neck

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT01365169 2026-01-07

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

Phase NA Recruiting

590 enrolled

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Somatostatinoma, Colorectal Neoplasms

NCT04227509 2025-12-31

Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Phase 2 Completed

53 enrolled

Nasopharyngeal Carcinoma

NCT05912582 2025-12-26

Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma

Not yet recruiting

60 enrolled

Nasopharyngeal Carcinoma

NCT07303023 2025-12-24

INCIPT-NPC

462 enrolled

Nasopharyngeal Carcinoma

NCT04004871 2025-12-11

Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2 Completed

60 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT05340270 2025-12-11

NeoTurbo

150 enrolled

Nasopharyngeal Carcinoma

NCT07277764 2025-12-11

REDEFINE

23 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT07188584 2025-12-09

Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

166 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT07248670 2025-11-25

Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC

252 enrolled

Phase NA Active not recruiting

Nasopharyngeal Carcinoma

NCT07248696 2025-11-25

Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial

32 enrolled

Nasopharyngeal Carcinoma

NCT07088861 2025-11-18

Validation of the 9th AJCC Staging System for NPC in Non-High-Incidence Areas in China

Active not recruiting

1,401 enrolled

Nasopharyngeal Carcinoma

NCT04925544 2025-10-21

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

13 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT06982300 2025-10-03

NACASOR

Phase 1/2 Recruiting

10 enrolled